Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/01/13 | $32,500,000 |
National Securities Corporation Roth Capital Partners Valence Life Sciences | undisclosed |
